Onkologie. 2010:4(6):353-356

Current perspective on surgical treatment of DCIS

Jiří Gatěk
Chirurgické oddělení nemocnice Atlas, Univerzita Tomáše Bati ve Zlíně

Breast screening results in an ever-increasing proportion of ductal carcinoma in situ (DCIS) in the spectrum of newly detected breast cancers.

It is a heterogeneous group of tumours. DCIS without microinvasion does not extend beyond the basal membrane and metastasize.

Although it accounts for up to 20 % of breast cancers in countries with advanced screening programmes, there is a lot of controversy over

its classification and treatment. Breast conservative procedures that are an alternative to mastectomy in early breast cancer have been

included in the treatment of DCIS as well. There is still no consensus on the width of the resection margin. Sentinel lymph node biopsy

(SLNB) is indicated in mastectomy. The indication of SLNB in conservative procedures is controversial. SLNB is performed in cases when

there is a risk of DCIS with foci of microinvasion and/or a risk of invasive carcinoma.

Keywords: DCIS, breast cancer, surgical treatment of DCIS

Published: January 1, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Gatěk J. Current perspective on surgical treatment of DCIS. Onkologie. 2010;4(6):353-356.
Download citation

References

  1. Cox Ch, Nguyen K, Gray R, et al. Importance of lymphatic mapping in ductal carcinoma in situ (DCIS): Why map DCIS? Am Surg 2001; 67: 513-521. Go to original source... Go to PubMed...
  2. Boland G, Chan K, Roberts S, et al. Value of the Van Nuys Prognostic index in prediction of recurrence of ductal carcinoma in situ after breast-conserving surgery: Br J Surg 2003; 90: 426-432. Go to original source... Go to PubMed...
  3. Nakamura S, Woo C, Silberman H, Breast-conserving therapy for ductal carcinoma in situ: 20-year experience with excision plus radiation therapy. Am J Surg 2002; 184: 403-409. Go to original source... Go to PubMed...
  4. Adamovich T, Simmons R. Ductal carcinoma in situ with microinvasion. Am J Surg 2003; 186: 112-116. Go to original source... Go to PubMed...
  5. Silver S, Tavassoli F, Mammary ductal carcinoma in situ with microinvasion. Cancer 1998; 82: 2382-2390. Go to original source...
  6. Fleming I, Cooper J, Henson D, et al. American joint committee on the classification of ductal carcinoma in situ 5th ed. Philadelphia Lippincott-Raven 1997.
  7. Silverstein M, The University of Southern California/Van Nuys prognostic index for ductal carcinoma in situ of the breast. Am J Surg 2003; 186: 337-343. Go to original source... Go to PubMed...
  8. Silverstein M, Poller D, Waisman J, et al. Prognostic classification of breast ductal carcinoma-in-situ. Lancet 1995; 345: 1154-1157. Go to original source... Go to PubMed...
  9. Silverstein M, Lagios M, Craig P, et al. A prognostic index for ductal carcinoma in situ of the breast. Cancer 1996; 77: 2267-2274. Go to original source...
  10. Gatěk J, Duben J, Dudešek B, Schon J. Výsledky konzervativní terapie u časného karcinomu prsu. Rozhl Chir 2000; 5: 201-205.
  11. Fisher E, Dingam, Wolmark N, et al. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol 1998; 16: 441-452. Go to original source... Go to PubMed...
  12. Julien J, Bijker N, Fentiman I. Radiotherapy in breast conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase 3 trial 10853. Lancet 335, 528-533.
  13. UK Coordinating Committee on Cancer Research (UKCCCR) Ductal Carcinoma in situ (DCIS) Working Party: Lancet 2003; 95-102.
  14. Meijnen P, Hester S, Oldenburg H, et al. Clinical outcome after selective treatment of patients diagnosed with ductal carcinoma in situ of the breast. Ann Surg Oncol 2007; 15: 235-243. Go to original source... Go to PubMed...
  15. Solin J, Fourquet A, Vicini F, et al. Salvage treatment for local recurrence after breast conserving surgery and radiation as initial treatment for mammographycally detected ductal carcinoma in situ of the breast. Cancer 2001; 91: 1090-1097. Go to original source...
  16. Gatěk J, Duben J, Hnátek L, et al. Chirurgická terapie duktálního karcinomu in situ. Rozhl Chir 2004; 11: 597-603.
  17. Schwartz G, Solin L, Olivotto I, et al. Concensus conference on the treatment of in Situ ductal carcinoma of the breast 1999: 22-25.
  18. Schwartz G, Veronesi U, Clouhg K, et al. Proceedings of the Consensus Conference on Breast Conservation, April 28 to May 1, 2005, Milan, Italy Cancer 2006; 107: 242-250. Go to original source... Go to PubMed...
  19. Kaufmann M, Morrow M, Minckwitz G. Locoreagional Treatment of Primary Breast Cancer. Cancer 2010; 1184-1191. Go to original source... Go to PubMed...
  20. Kelly T, Kim J, Patric R, et al. Axillary lymph node metastases on patients with a final diagnosis of ductal carcinoma on situ. Am J Surg 2003; 186: 368-370. Go to original source... Go to PubMed...
  21. Schwartz G, Giuliano A, Veronesi U. Proceedings of the consensus conference on the role of sentinel lymph node biopsy in carcinoma of the breast April 2001: 19-22. Philadelphia Pennsylvania Cancer 2002; 94: 2542-2551. Go to original source...
  22. Pendas S, Dauway E, Giuliano R, et al. Sentinel node biopsy in ductal carcinoma in situ patients. Ann Surg Oncol 2000; 7: 15-20. Go to original source... Go to PubMed...
  23. Riveradeneira D, Simmons R, Christos P, et al. Predictive factors associated with axillary lymph node metastases in T1a and T1b breast carcinomas: analysis in more than 900 patients. J Am Call Surg 2000; 191: 1-8. Go to original source... Go to PubMed...
  24. Zavotsky J, Hansen N, Brennan M, et al. Lymph node metastasis from ductal carcinoma in situ with microinvasion. Cancer 1999; 85: 2439-2443. Go to original source...
  25. Klauber-DeMore N, Tan L, Liberman L, et al. Sentinel node biopsy: is it indicated in patients with high risk ductal carcinoma in situ and ductal carcinoma in situ with microinvasion? Am Surg Oncol 2000; 7: 636-642. Go to original source... Go to PubMed...
  26. McMasters K, Chao C, Wong S. Sentinel lymph node in patients with ductal carcinoma in situ Cancer 2002; 95: 15-20. Go to original source... Go to PubMed...
  27. Meijnen P, Oldenburg H, Loo C, et al. Risk of invasion and axillary lymph node metastasis in ductal carcinoma in situ diagnosed by core- needle biopsy. Br J Surg 2007; 94: 952-956. Go to original source... Go to PubMed...
  28. Julian T, Land S, Fourchotte V, et al. Is Sentinel Node Biopsy Necessary in Conservatively Treated DCIS? Ann Surg Oncol 2007; 14: 2202-2208. Go to original source... Go to PubMed...
  29. Cody H. Sentinel Lymph Node Biopsy for DCIS: Are We Approaching Consensus? Ann Surg Oncol 2007; 14(8): 2179-5181. Go to original source... Go to PubMed...
  30. Intra M, Veronesi P, Gentili O, et al. Sentinel lymph node biopsy is feasible even after total Mastectomy. J Surg Oncol 2007; 95: 175-189. Go to original source... Go to PubMed...
  31. Intra M, Rotmensz N, Veronesi P, et al. Sentinel node biopsy is not a standard procedure in ductal carcinoma in situ of the breast. Ann Surg 2008; 315-319. Go to original source... Go to PubMed...
  32. Lara J, Young S, Velilla R, et al. The relevance of occult micrometastases in ductal carcinoma in situ (DCIS) a clinicopatological study with long-term follow-up. Cancer 2003; 98: 2105-2113. Go to original source... Go to PubMed...
  33. Weaver D. Occult, ,micrometastasis" in ductal carcinoma in situ Cancer 2003; 15: 2083-2087. Go to original source... Go to PubMed...
  34. Neuschatz A, DiPetrillo T, Steinhoff M, et al. The value of breast lumpectomy margin assessment as predictor of residual tumor burden in ductal carcinoma in situ of the breast: Cancer 2002; 94: 1917-1924.
  35. Chagpar A, Yen T, Sahin A, et al. Intraoperative margin assessment reduces reexcision rates in patients with ductal carcinoma in situ treated with breast-conserving surgery. Am J Surg 2003; 186: 371-377. Go to original source... Go to PubMed...




Oncology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.